Scientists discover a pharmaceutical competitor that will help people lose weight with less nausea

Wooli, eat your heart. In a new research sheet, scientists say they have discovered a natural hormone that may help people lose weight while avoiding the side effects associated with arglotide (the active ingredient in Ozambek and Ugovi) and similar medications.

A team of researchers in Stanford Medicine conducted the study, Published Last week in the Journal of Nature. With the help of artificial intelligence, the previously unknown peptide team identifies it seems to reduce the appetite and weight of mice and mini pigs without causing nausea or other digestive symptoms. More studies will be needed to verify the integrity and effectiveness of the molecule in people, but the results provide a confusing inspection of what could be the future of obesity.

The appearance of Smaglutide and similar drugs in recent years have been Truly For the field of obesity medicine. These medications, also used for type 2 diabetes, have proven that they are much more effective in helping people lose weight than diet and exercise alone, with results ranging between them. 15 % to 20 % She lost weight in clinical trials. Semaglutide works by GLP-1 simulation, a hormone that helps regulate our appetite and metabolism, among other functions (some drugs such as Tirzepatide simulates GLP-1 and other relevant hormones).

Although these medications are usually caused by annoying GI symptoms, and rarely cause more severe complications such as stomach (stomach paralysis). Scientists are also working and developing newer generation drugs that can provide a greater weight loss or provide other means of amenities, such as being available as birth control pills. In this context, Stanford’s medical researchers have created a new strategy to find their drug candidates.

Many hormones in the body are only activated when their spoles are passed by specific enzymes. These sects are called Prohormones, and the family of the enzymes cut by the transformer is called the transformer. The researchers in one of these enzymes looked at the prohormone convertse 1/3, which is known to help in producing the GLP-1. They decided to find out if they could find other useful hormones related to the hunger that the enzyme produces naturally. To accelerate this discovery process significantly, they developed a computer algorithm (dubbable peptide index) to narrow the list of potential molecules that suit their standards.

This examination found an initial boost of 373 prohormones that could result from about 2,700 with a different bitide (often peptides for large protein building blocks, but can have distinctive functions of their own in the body). From there, the researchers tested 100 with peptide known or suspected that it could affect the hunger engine in the brain (including the GLP-1 comparison). In the end, they identified a single molecule that looks particularly promising, which is 12 with a prolide of amino acids called BINP2, or BRP.

Then the scientists tested BRP on laboratory mice and mini pigs (it is believed that the miniipigs is closely similar to people Metabolism). They found that one dose of BRP was greatly reduced from the appetite of both animals in the short term, and sometimes up to 50 %. The obese mice that were given BRP lost weight significantly over a period of two weeks, with most of this fat weight.

Additional experiments have shown that the BRP effects that reduce hunger on the brain do not involve the GLP-1 receptors at all, and that they simply did not cause animal experiences of the symptoms of the digestive system usually associated with the drug-like drugs. Dosage animals also did not face changes in their movement, the level of anxiety behavior, or water, which indicates that BRP can safely withstand it when taking it as a medicine.

“The receptors targeted by the semules are found in the brain, but also in the intestine, pancreas and other tissues. For this reason OzemPIC has extensive effects including slowing the movement of food through the digestive system and lowering blood sugar levels.” Senior researchers Catherine Svinson, Assistant Professor in Pathology in Stanford, said in A. statement From the university. “On the contrary, the BRP appears to be behaved in the underneath, which controls appetite and metabolism.”

The team’s results, of course, are preliminary at this stage. It will take more time and research, including early successful clinical trials in humans, before BRP is seen as the next big thing in obesity. But the team’s discovery is the latest that indicates that Semaglutide has truly sparked the sea to treat obesity. There are now dozens of experimental drugs in the pipeline threatening to compete or even bypass OzemPIC/Wegov, including Various combinations From semaglutide. For their part, Svenesson and her colleagues have already submitted patents on the BRP, and have participated in establishing a company that hopes to develop the molecule for clinical use.

No medication comes without side effects, but the future of obesity treatment can one day be much lower nausea.